From Yahoo Finance: 2025-05-30 23:57:00

Investment firms Carlyle Group Inc. and SK Capital Partners, along with Beacon Parent Holdings, have completed the tender offer to acquire all outstanding common stock of bluebird bio, Inc. The transaction offers $3.00 per share plus a contingent value right or $5.00 per share in cash, set to be finalized through a merger on June 2, 2025.

Bluebird bio, Inc., a biotechnology company specializing in gene therapies for genetic diseases, faced financial challenges with a high debt-to-capital ratio of 0.82 and a low current ratio of 0.55. Carlyle and SK Capital Partners made a deal for $3 in cash and a $6.84 contingent value, securing approvals from EU, China, and Turkey.

The acquisition of bluebird bio, Inc. by Carlyle and SK Capital Partners is expected to proceed without a vote from stockholders, following Delaware’s General Corporation Law. Shareholders have the option to receive immediate cash through an amended buyout agreement instead of potential future payments.

Read more: bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital